Evaluation of Therapeutic Use of Antifibrinolytics in Cats.

Limited data are available regarding the use of the antifibrinolytic drugs tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) in cats. This study aimed to evaluate the indications for the use of TXA and EACA in cats and to describe dosing regimens used, occurrence of adverse events, and patient outcomes. This was a retrospective multicenter study. Medical databases were searched for feline patients billed for TXA or EACA between 2015 and 2021. Thirty-five cats met the inclusion criteria; 86% received TXA and 14% received EACA. The most common indication was nontraumatic hemorrhage (54%), followed by traumatic hemorrhage (17%) and elective surgery (11%). The median dose was 10 mg/kg for TXA and 50 mg/kg for EACA. Overall, 52% of cats survived to discharge. Potential adverse events were noted in 7/35 (20%) patients. Of these, 29% survived to discharge. No standardized dosing regimen was identified; rather, dose, dosing interval, and duration of administration varied markedly between patients. Administration was potentially associated with severe adverse events, although the retrospective design makes it difficult to establish a causal association with antifibrinolytic use. This study provides a base for future prospective studies by giving an insight into the use of antifibrinolytic drugs in cats.

In vitro compatibility testing of canine and rabbit blood.

OBJECTIVE: To determine the in vitro compatibility of rabbit and canine blood using both a tube and slide agglutination crossmatch technique and to compare the results obtained from these 2 methods. DESIGN: Prospective observational laboratory study from January to March 2020. SETTING: University veterinary teaching hospital. ANIMALS: Six client-owned rabbits ≥3.5 kg undergoing phlebotomy for a clinical reason. "Pigtail" blood samples from 3 dog erythrocyte antigen (DEA) 1-positive and 3 DEA 1-negative canine packed red blood cell units. INTERVENTIONS: Blood from each rabbit was crossmatched with a single unit of canine blood using both a standard laboratory tube agglutination technique and a simple slide agglutination method with each rabbit/canine unit serving as its own intraassay control. Tube crossmatches were evaluated for agglutination both macro- and microscopically and assessed for hemolysis. Slide crossmatches were assessed for the presence of agglutination both macro- and microscopically.  MEASUREMENTS AND MAIN RESULTS: All crossmatches were incompatible. Varying degrees of agglutination were seen for all crossmatches. Hemolysis was observed with all minor tube crossmatches. Results of both crossmatch techniques were in close agreement.  CONCLUSIONS: The crossmatch results in this present study strongly demonstrate in vitro incompatibility between canine and rabbit blood. Agreement between the 2 techniques in this study indicates that the slide agglutination technique may be quicker, require less blood, and provide reliable results in exclusively assessing the compatibility of canine and rabbit blood. Based on the results of this study, emergency xenotransfusion of canine blood to rabbits cannot be recommended.